ABSTRACT
Context Many endocrine and metabolic disorders are seen in patients with HIV infection. Various comorbidities have been reported at a higher rate in HIV positive individuals, some at an earlier age. Since metabolic syndrome and its determinants are slowly developing, studies are needed in this regard.
Aims The study aimed to analyze various parameters associated with the metabolic syndrome in HIV positive individuals and stratify subjects based on their treatment regimens, and present a brief comparison based on the same.
Settings and Design A cross sectional study involving 155 participants was conducted at a tertiary care centre in Western India.
Materials and Methods Detailed history and clinical examination was carried out. Routine investigations were done and parameters of interest to the study were then analysed based on AHA/NHLBI definitions.
Statistical Analysis used Univariate analysis of all parameters. Multiple logistic regression for statistically significant parameters.
Results and Conclusion Deranged HDL cholesterol was the most common component of the metabolic syndrome seen amongst all participants (53.8%) which was significantly higher in the treatment naïve group (P = 0.001). The difference between the incidence of metabolic syndrome between the ART naïve group and patients receiving ART was not significant. Males had a significantly higher prevalence of metabolic syndrome than females (26.3%>12.4%, P = 0.026). There was a significant difference in the incidence between the Zidovudine and Tenofovir treatment groups(P=0.02). Patients on the TLE (Tenofovir, Lamivudine, and Efavirenz) regimen had the lowest prevalence (4.2%) of metabolic syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Seth G.S. Medical College and K.E.M Hospital, Mumbai gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email id – kavitajoshi{at}kem.edu
Email id - uditsaraf274{at}gmail.com
Email id – rushabhyg{at}gmail.com
Source(s) of support: nil.
Conflicting Interest: none – for all authors.
Data Availability
All data produced in the present work are contained in the manuscript
